 | • レポートコード：MRC2303L203 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、228ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートでは、2021年に4,433.31百万ドルであった世界の強直性脊椎炎（AS）市場規模が2022年に4,789.70百万ドルとなり、2027年までに年平均8.21％拡大して7,119.88百万ドルに達すると予測されています。本書では、強直性脊椎炎（AS）の世界市場を対象に総合的に調査・分析を行い、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、薬剤別（シムジア、コセンティクス、エンブレル、フミラ、レミケード）分析、分子種類別（生物製剤、小分子）分析、作用機序別（COX阻害剤、TNF阻害剤）分析、投与経路別（経口薬、非経口薬）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの構成でまとめております。なお、本書に掲載されている企業情報には、Abbvie Inc.、Amgen Inc.、Biothera Pharmaceuticals, Inc.、Bristol-Myers Squibb、C.H. Boehringer Sohn AG & Ko. KG、Cadila Healthcare Limited、Celgene Corporation、Celltrion、Eisai Co., Ltd、Eli Lilly and Company、F. Hoffmann-La Roche AG、Hetero Drugs Limitedなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の強直性脊椎炎（AS）市場規模：薬剤別 - シムジアの市場規模 - コセンティクスの市場規模 - エンブレルの市場規模 - フミラの市場規模 - レミケードの市場規模 ・世界の強直性脊椎炎（AS）市場規模：分子種類別 - 生物製剤の市場規模 - 小分子の市場規模 ・世界の強直性脊椎炎（AS）市場規模：作用機序別 - COX阻害剤の市場規模 - TNF阻害剤の市場規模 ・世界の強直性脊椎炎（AS）市場規模：投与経路別 - 経口薬の市場規模 - 非経口薬の市場規模 ・世界の強直性脊椎炎（AS）市場規模：地域別 - 南北アメリカの強直性脊椎炎（AS）市場規模 アメリカの強直性脊椎炎（AS）市場規模 カナダの強直性脊椎炎（AS）市場規模 ブラジルの強直性脊椎炎（AS）市場規模 ... - アジア太平洋の強直性脊椎炎（AS）市場規模 日本の強直性脊椎炎（AS）市場規模 中国の強直性脊椎炎（AS）市場規模 インドの強直性脊椎炎（AS）市場規模 韓国の強直性脊椎炎（AS）市場規模 台湾の強直性脊椎炎（AS）市場規模 ... - ヨーロッパ/中東/アフリカの強直性脊椎炎（AS）市場規模 イギリスの強直性脊椎炎（AS）市場規模 ドイツの強直性脊椎炎（AS）市場規模 フランスの強直性脊椎炎（AS）市場規模 ロシアの強直性脊椎炎（AS）市場規模 ... - その他地域の強直性脊椎炎（AS）市場規模 ・競争状況 ・企業情報 |
The Global Ankylosing Spondylitis Market size was estimated at USD 4,433.31 million in 2021 and expected to reach USD 4,789.70 million in 2022, and is projected to grow at a CAGR 8.21% to reach USD 7,119.88 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Ankylosing Spondylitis to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Drug, the market was studied across Cimzia, Cosentyx, Enbrel, Humira, Remicade, and Simponi.
Based on Type of Molecule, the market was studied across Biologics and Small Molecules.
Based on Mechanism Of Action, the market was studied across COX Inhibitors and TNF Inhibitors.
Based on Route Of Administration, the market was studied across Oral and Parenteral.
Based on Dosage Forms, the market was studied across Liquid and Solid.
Based on End User, the market was studied across Clinics and Hospitals.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Ankylosing Spondylitis market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Ankylosing Spondylitis Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Ankylosing Spondylitis Market, including Abbvie Inc., Amgen Inc., Biothera Pharmaceuticals, Inc., Bristol-Myers Squibb, C.H. Boehringer Sohn AG & Ko. KG, Cadila Healthcare Limited, Celgene Corporation, Celltrion, Eisai Co., Ltd, Eli Lilly and Company, F. Hoffmann-La Roche AG, Hetero Drugs Limited, Izana Bioscience, Johnson & Johnson Services, Inc., Merck & Co., Inc, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc, Reliance Life Sciences, Samsung Bioepis Co., Ltd., Sandoz International GmbH, Sanofi SA, Shanghai Pharmaceuticals Holding Co., Ltd., Trinity Biotech Ireland, UCB Inc., and Xian Janssen Pharmaceutical Ltd.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Ankylosing Spondylitis Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Ankylosing Spondylitis Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Ankylosing Spondylitis Market?
4. What is the competitive strategic window for opportunities in the Global Ankylosing Spondylitis Market?
5. What are the technology trends and regulatory frameworks in the Global Ankylosing Spondylitis Market?
6. What is the market share of the leading vendors in the Global Ankylosing Spondylitis Market?
7. What modes and strategic moves are considered suitable for entering the Global Ankylosing Spondylitis Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidences of ankylosing spondylitis
5.1.1.2. Growing awareness about diagnostics and treatments for the disease
5.1.2. Restraints
5.1.2.1. Expiry patent of the drugs
5.1.3. Opportunities
5.1.3.1. Increase in research and development expenditure for the treatment of the spondylitis
5.1.3.2. Introduction of the biosimilars
5.1.4. Challenges
5.1.4.1. High cost of treatment and limited of skilled surgeons and physiotherapists
5.2. Cumulative Impact of COVID-19
6. Ankylosing Spondylitis Market, by Drug
6.1. Introduction
6.2. Cimzia
6.3. Cosentyx
6.4. Enbrel
6.5. Humira
6.6. Remicade
6.7. Simponi
7. Ankylosing Spondylitis Market, by Type of Molecule
7.1. Introduction
7.2. Biologics
7.3. Small Molecules
8. Ankylosing Spondylitis Market, by Mechanism Of Action
8.1. Introduction
8.2. COX Inhibitors
8.3. TNF Inhibitors
9. Ankylosing Spondylitis Market, by Route Of Administration
9.1. Introduction
9.2. Oral
9.3. Parenteral
10. Ankylosing Spondylitis Market, by Dosage Forms
10.1. Introduction
10.2. Liquid
10.3. Solid
11. Ankylosing Spondylitis Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Hospitals
12. Americas Ankylosing Spondylitis Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Ankylosing Spondylitis Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Ankylosing Spondylitis Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.1.1. Quadrants
15.1.2. Business Strategy
15.1.3. Product Satisfaction
15.2. Market Ranking Analysis, By Key Player
15.3. Market Share Analysis, By Key Player
15.4. Competitive Scenario
15.4.1. Merger & Acquisition
15.4.2. Agreement, Collaboration, & Partnership
15.4.3. New Product Launch & Enhancement
15.4.4. Investment & Funding
15.4.5. Award, Recognition, & Expansion
16. Company Usability Profiles
16.1. Abbvie Inc.
16.1.1. Business Overview
16.1.2. Key Executives
16.1.3. Product & Services
16.2. Amgen Inc.
16.2.1. Business Overview
16.2.2. Key Executives
16.2.3. Product & Services
16.3. Biothera Pharmaceuticals, Inc.
16.3.1. Business Overview
16.3.2. Key Executives
16.3.3. Product & Services
16.4. Bristol-Myers Squibb
16.4.1. Business Overview
16.4.2. Key Executives
16.4.3. Product & Services
16.5. C.H. Boehringer Sohn AG & Ko. KG
16.5.1. Business Overview
16.5.2. Key Executives
16.5.3. Product & Services
16.6. Cadila Healthcare Limited
16.6.1. Business Overview
16.6.2. Key Executives
16.6.3. Product & Services
16.7. Celgene Corporation
16.7.1. Business Overview
16.7.2. Key Executives
16.7.3. Product & Services
16.8. Celltrion
16.8.1. Business Overview
16.8.2. Key Executives
16.8.3. Product & Services
16.9. Eisai Co., Ltd
16.9.1. Business Overview
16.9.2. Key Executives
16.9.3. Product & Services
16.10. Eli Lilly and Company
16.10.1. Business Overview
16.10.2. Key Executives
16.10.3. Product & Services
16.11. F. Hoffmann-La Roche AG
16.11.1. Business Overview
16.11.2. Key Executives
16.11.3. Product & Services
16.12. Hetero Drugs Limited
16.12.1. Business Overview
16.12.2. Key Executives
16.12.3. Product & Services
16.13. Izana Bioscience
16.13.1. Business Overview
16.13.2. Key Executives
16.13.3. Product & Services
16.14. Johnson & Johnson Services, Inc.
16.14.1. Business Overview
16.14.2. Key Executives
16.14.3. Product & Services
16.15. Merck & Co., Inc
16.15.1. Business Overview
16.15.2. Key Executives
16.15.3. Product & Services
16.16. Novartis AG
16.16.1. Business Overview
16.16.2. Key Executives
16.16.3. Product & Services
16.17. Pfizer Inc.
16.17.1. Business Overview
16.17.2. Key Executives
16.17.3. Product & Services
16.18. Regeneron Pharmaceuticals, Inc
16.18.1. Business Overview
16.18.2. Key Executives
16.18.3. Product & Services
16.19. Reliance Life Sciences
16.19.1. Business Overview
16.19.2. Key Executives
16.19.3. Product & Services
16.20. Samsung Bioepis Co., Ltd.
16.20.1. Business Overview
16.20.2. Key Executives
16.20.3. Product & Services
16.21. Sandoz International GmbH
16.21.1. Business Overview
16.21.2. Key Executives
16.21.3. Product & Services
16.22. Sanofi SA
16.22.1. Business Overview
16.22.2. Key Executives
16.22.3. Product & Services
16.23. Shanghai Pharmaceuticals Holding Co., Ltd.
16.23.1. Business Overview
16.23.2. Key Executives
16.23.3. Product & Services
16.24. Trinity Biotech Ireland
16.24.1. Business Overview
16.24.2. Key Executives
16.24.3. Product & Services
16.25. UCB Inc.
16.25.1. Business Overview
16.25.2. Key Executives
16.25.3. Product & Services
16.26. Xian Janssen Pharmaceutical Ltd
16.26.1. Business Overview
16.26.2. Key Executives
16.26.3. Product & Services
17. Appendix
17.1. Discussion Guide
17.2. License & Pricing